11 Nov 2020 09:46
The information contained within this announcement is considered by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No.596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.
Cathay International Holdings Limited
("Cathay" or the "Company")
Results of the Tender Offer
Hong Kong, 11 November 2020 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, announced on 16 October 2020 the details of a Tender Offer on behalf of Circle Finance Limited and on 3 November 2020 the result of Special General Meeting. The Company today announces the results of the Tender Offer.
Capitalised terms not otherwise defined in the text of this announcement have the meanings given in the Company's announcement of 16 October 2020.
Results of Tender Offer
The Tender Offer closed for acceptances at 11.00 a.m. (London Time) on 10 November 2020 in accordance with its terms. The Company has received valid application under the Tender Offer in respect of 509,967,002 Common Shares and A Shares representing 94.3 per cent of the Common Shares and A Shares available pursuant to the Tender Offer. It is anticipated that settlement of the consideration to which any Shareholder or DI Holder is entitled pursuant to Tender Offer will be made on or around 1 December 2020.
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller)
|
Tel: +852 2828 9289 |
SPARK Advisory Partners Limited (Financial Advisor) Andrew Emmott James Keeshan |
Tel: +44 (0) 20 3368 3555
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 1,300 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.